Characterization of human brain pharmacokinetics using a two-compartment model.

Area of Science:

• Pharmacokinetics
• Neuroimaging
• Spectroscopy

Background:

• Recent advances in brain spectroscopy enable noninvasive characterization of fluorinated psychotropic compounds.
• Understanding drug distribution and elimination in the brain is crucial for psychotropic medication efficacy.
• Existing models may not fully capture the multicompartment dynamics of drug behavior in the brain.

Purpose of the Study:

• To develop and validate a two-compartment pharmacokinetic model for analyzing 19F MRS data of psychotropic compounds in the human brain.
• To systematically characterize drug concentration time courses and derive key pharmacokinetic parameters.
• To apply the model to calculate brain volume of distribution and clearance for fluvoxamine.

Main Methods:

• Development of a two-compartment pharmacokinetic model based on differences in drug elimination half-lives.
• Utilizing 19F magnetic resonance spectroscopy (19F MRS) to measure drug concentrations in the brain over time.
• Application of the model to previously published data on fluvoxamine plasma and brain elimination half-lives.

Main Results:

• The model successfully characterized 19F MRS data for psychotropic compounds.
• Calculated brain volume of distribution for fluvoxamine was 1.12 L/kg (± 0.2 SEM).
• Calculated clearance for fluvoxamine was 1.01 L/hour (± 0.12 SEM), with brain bioavailability of 1.85 (± 0.23 SEM).

Conclusions:

• The developed pharmacokinetic model provides a robust method for deriving essential drug parameters from 19F MRS data.
• The model reflects the multicompartment pharmacokinetics of fluvoxamine, evidenced by differing brain and plasma elimination half-lives.
• This approach can be extended to characterize the pharmacokinetics of other fluorinated psychotropic drugs.